

Supporting Information

An Improved Method for the Synthesis of *F*-BODIPYs from Dipyrrens and Bis(dipyrrin)s

Travis Lundrigan, Alexander E.G. Baker, Lauren E. Longobardi, Tabitha E. Wood,[†] Deborah A. Smithen, Sarah M. Crawford, T. Stanley Cameron, Alison Thompson*

*Department of Chemistry, Dalhousie University, P.O. Box 15000, Halifax, NS, B3H 4R2, Canada.
Alison.Thompson@dal.ca*

[†]*Current address: Department of Chemistry, The University of Winnipeg, 515 Portage Avenue, Winnipeg, Manitoba, R3B 2E9, Canada*

1.1 GENERAL EXPERIMENTAL SECTION	2
1.2 EXPERIMENTAL PROCEDURES AND CHARACTERIZATION DATA	3
1,3,5,7-Tetramethyl-2-octyl-8- <i>H</i> -4-bora-3a,4a-diaza- <i>s</i> -indacene (1BF ₂)	3
1,3,5,7-Tetramethyl-2-ethyl-8- <i>H</i> -4-bora-3a,4a-diaza- <i>s</i> -indacene (2BF ₂)	3
1,3,5,7-Tetramethyl-2,6-diethyl-8- <i>H</i> -4-bora-3a,4a-diaza- <i>s</i> -indacene (3BF ₂)	5
1,3,5,7-Tetramethyl-2,6-diethyl-8-phenyl-4-bora-3a,4a-diaza- <i>s</i> -indacene (5BF ₂)	6
3-Methyl-1,5,7-triethyl-2-ethylcarboxylato-8- <i>H</i> -4-bora-3a,4a-diaza- <i>s</i> -indacene (6BF ₂)	7
1,3,6-Trimethyl-7-ethyl-2-8- <i>H</i> -4-bora-3a,4a-diaza- <i>s</i> -indacene (7BF ₂)	7
8-Phenyl-4-bora-3a,4a-diaza- <i>s</i> -indacene (8BF ₂)	8
1,7-Bis(5-((<i>Z</i>)-(4-ethyl-3,5-dimethyl-2 <i>H</i> -pyrrol-2-ylidene)methyl)-2,4-dimethyl-1 <i>H</i> -pyrrol-3-yl)hexane dihydrobromide (9HBr)	8
1,7-Bis(1,3,5,7-tetramethyl-2-ethyl-8- <i>H</i> -4-bora-3a,4a-diaza- <i>s</i> -indacene)hexane (9BF ₂)	10
1,7-Bis(5-((<i>Z</i>)-(4-ethyl-3,5-dimethyl-2 <i>H</i> -pyrrol-2-ylidene)methyl)-2,4-dimethyl-1 <i>H</i> -pyrrol-3-yl)heptane dihydrobromide (10HBr)	10
1,7-Bis(1,3,5,7-tetramethyl-2-ethyl-8- <i>H</i> -4-bora-3a,4a-diaza- <i>s</i> -indacene)heptane (10BF ₂)	12
1,3,5,7-Tetramethyl-8- <i>H</i> -4-bora-3a,4a-diaza- <i>s</i> -indacene (4BF ₂)	12
1.4 NMR SPECTRA	14
1,3,5,7-Tetramethyl-2-octyl-8- <i>H</i> -4,4'-dichloro-bora-3a,4a-diaza- <i>s</i> -indacene (1BF ₂)	14
1,3,5,7-Tetramethyl-2-ethyl-8- <i>H</i> -4,4'-dichloro-bora-3a,4a-diaza- <i>s</i> -indacene (2BF ₂)	14
3-Methyl-1,5,7-triethyl-2-ethylcarboxylato-8- <i>H</i> -4-bora-3a,4a-diaza- <i>s</i> -indacene (6BF ₂)	15
1,3,6-Trimethyl-7-ethyl-2-8- <i>H</i> -4-bora-3a,4a-diaza- <i>s</i> -indacene (7BF ₂)	15
1,7-Bis(1,3,5,7-tetramethyl-2-ethyl-8- <i>H</i> -4-bora-3a,4a-diaza- <i>s</i> -indacene)hexane (9BF ₂)	16
1,7-Bis(5-((<i>Z</i>)-(4-ethyl-3,5-dimethyl-2 <i>H</i> -pyrrol-2-ylidene)methyl)-2,4-dimethyl-1 <i>H</i> -pyrrol-3-yl)heptane dihydrobromide (10HBr)	16
1,7-Bis(1,3,5,7-tetramethyl-2-ethyl-8- <i>H</i> -4-bora-3a,4a-diaza- <i>s</i> -indacene)heptane (10BF ₂)	17
1.4 REFERENCES	17

1.1 General Experimental Section

All ^1H NMR (500 MHz), ^{13}C NMR (125 MHz) and ^{11}B NMR (160 MHz) spectra were recorded using a 500 MHz spectrometer. Chemical shifts are expressed in parts per million (ppm) using the solvent signal [CDCl_3 (^1H 7.26 ppm; ^{13}C 77.16 ppm); $\text{MeOD-}d_4$ (^1H 3.31 ppm, ^{13}C 49.00 ppm)] as an internal reference for ^1H and ^{13}C , and $\text{BF}_3\cdot\text{OEt}_2$ as an external reference for ^{11}B at 0 ppm. Splitting patterns are indicated as follows: br, broad; s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. All coupling constants (J) are reported in Hertz (Hz). Mass spectra were obtained using ion trap (ESI) instruments operating in positive mode. Column chromatography, as indicated, was performed using 230-400 mesh ultra pure silica. Dipyrrens **2**,¹ **3**,² **5**,³ **7**⁴ and **8**⁵ were prepared using literature procedures. The free-bases were obtained by adding concentrated ammonium hydroxide (28%) to a suspension of the HBr salt in diethyl ether. Within 15 minutes, the formation of a yellow precipitate (NH_4Br) was observed. Distilled water was used to extract the by-products. The resulting organic fraction was dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure to give the title compound. Compounds were dried under vacuum before use. Compounds **3BF₂-5BF₂**⁶ and **8BF₂**⁷ have been previously reported.


General Procedure for the Synthesis of *F*-BODIPYs (GP1)

Each dipyrren was used as the free-base. The dipyrren (50 mg) was dissolved in anhydrous dichloromethane (20 mL) and a solution of LiHMDS [1.1 eq.; 2.2 eq. for the bis(dipyrren)s] in anhydrous tetrahydrofuran was added drop-wise. The reaction was stirred for two hours. A solution of $\text{BF}_3\cdot\text{OEt}_2$ [1 eq.; 2 eq. for bis(dipyrren)s] in anhydrous dichloromethane was then added to the reaction mixture drop-wise, and stirring was

continued for another three hours. Upon completion of the reaction, the mixture was filtered over a pad of Celite, and silica if necessary, in both cases flushing with dichloromethane. The solutions were then concentrated *in vacuo* to obtain the *F*-BODIPY product.


1.2 Experimental Procedures and Characterization Data

1,3,5,7-Tetramethyl-2-octyl-8-*H*-4-bora-3a,4a-diaza-*s*-indacene (**1BF₂**)




Using **GP1**, compound **1BF₂** was synthesized from the corresponding free-base dipyrin. Bright orange solid (55 mg, 98 %). δ_{H} (500 MHz, CDCl₃) 6.94 (s, 1H), 2.49 (s, 6H), 2.34 (t, $J = 7.6$, 4H), 2.15 (s, 6H), 1.43-1.39 (m, 4H), 1.30-1.27 (m, 20H), 0.89 (t, $J = 6.8$, 6H); δ_{C} (125 MHz, CDCl₃) 155.0, 137.1, 132.5, 130.4, 118.6, 32.0, 30.3, 29.7, 29.6, 29.4, 24.2, 22.8, 14.2, 12.8, 9.7; δ_{B} (160 MHz, CDCl₃) 0.90 (t, $J_{\text{B-F}} = 34$); LRMS-ESI (m/z): 495.4 [M + Na]⁺; HRMS-ESI (m/z): [M + Na]⁺ calcd for C₂₉H₄₇BF₂N₂Na 495.3693; found 495.3709.

1,3,5,7-Tetramethyl-2-ethyl-8-*H*-4-bora-3a,4a-diaza-*s*-indacene (**2BF₂**)




Using **GP1**, compound **2BF₂** was synthesized from the corresponding free-base dipyrrens.¹ Bright orange solid (55 mg, 91 %). δ_{H} (500 MHz, CDCl₃) 6.99 (s, 1H), 6.00 (s, 1H), 2.51 (s, 6H), 2.39 (q, $J = 7.5$, 2H), 2.23 (s, 3H), 2.17 (s, 3H), 1.07 (t, $J = 7.6$, 3H); δ_{C} (125 MHz, CDCl₃) 156.6, 155.2, 140.0, 137.8, 133.2, 132.9, 132.6, 119.4, 118.4, 17.4, 14.7, 14.6, 12.8, 11.4, 9.6; δ_{B} (160 MHz, CDCl₃) 0.89 (t, $J_{\text{B-F}} = 33$); LRMS-ESI (m/z): 299.2 [M + Na]⁺; HRMS-ESI (m/z): [M + Na]⁺ calcd for C₁₅H₁₉BF₂N₂Na 299.1502; found 299.1514.




Crystal data for compound **2BF₂**: C₁₅H₁₉BF₂N₂, MM = 276.14 g/mol, colourless prism crystal 0.26 x 0.23 x 0.17 mm; triclinic, space group P₁ (#2), a = 8.6184(9) Å, b = 9.2516(10) Å, c = 10.4144(10) Å, V = 730.81(13) Å³, Z = 2, $\rho = 1.255$ g/cm³, $\mu(\text{MoK}\alpha) = 0.71070$ cm⁻¹, 2721 reflections (1612 unique, $R_{\text{int}} = 0.040$), R = 0.0476, $R_w = 0.0548$, GOF = 1.077.

1,3,5,7-Tetramethyl-2,6-diethyl-8-*H*-4-bora-3a,4a-diaza-*s*-indacene (**3BF₂**)




Using **GPI1**, compound **3BF₂** was synthesized from the corresponding free-base dipyrin.² Bright red solid (56 mg, 94 %). δ_{H} (500 MHz, CDCl₃) 6.93 (s, 1H), 2.49 (s, 6H), 2.36 (q, $J = 7.6$, 4H), 2.14 (s, 6H), 1.05 (t, $J = 7.6$, 6H); δ_{C} (125 MHz, CDCl₃) 154.7, 136.7, 132.5, 131.7, 118.7, 17.4, 14.7, 12.6, 9.4; δ_{B} (160 MHz, CDCl₃) 0.76 (t, $J_{\text{B-F}} = 32$). NMR data matches that previously reported.⁶



Crystal data for compound **3BF₂**: C₁₇H₂₃BF₂N₂, MM = 304.19 g/mol, colourless needle crystal 0.34 x 0.11 x 0.08 mm; triclinic, space group P₁ (#2), a = 9.3694(16) Å, b = 12.210(2) Å, c = 8.6351(16) Å, V = 833.1(3) Å³, Z = 2, $\rho = 1.213$ g/cm³, $\mu(\text{MoK}\alpha) = 0.71070$ cm⁻¹, 3365 reflections (1947 unique, $R_{\text{int}} = 0.090$), R = 0.0693, $R_w = 0.0775$, GOF = 0.944.


1,3,5,7-Tetramethyl-2,6-diethyl-8-phenyl-4-bora-3a,4a-diaza-s-indacene (5BF₂)



Method 1: Using **GP1**, compound **5BF₂** was synthesized from the corresponding free-base dipyrin.³ Bright orange solid (50 mg, 88 %).


Method 2: To a solution of 5,5'-(phenylmethylene)bis(3-ethyl-2,4-dimethyl-1*H*-pyrrole) (800 mg, 2.39 mmol) in anhydrous DCM (80 mL) under nitrogen was added DDQ (543 mg, 2.39 mmol). The reaction mixture was stirred at room temperature for an hour before LiHMDS in anhydrous hexane (1.0 M, 7.9 mL) was added. The reaction mixture was stirred for another hour before the addition of neat BF₃•OEt₂ (0.30 mL, 2.39 mmol). After three hours the reaction mixture was filtered over Celite, flushing with dichloromethane. The filtrate was washed with 0.1 M NaOH (25 mL), 1 M HCl (25 mL) and brine (25 mL). The organic fraction was dried over Na₂SO₄ and concentrated *in vacuo*. The resulting solid was purified via filtration over a pad of silica eluting with DCM. Removal of the solvent *in vacuo* afforded a bright orange solid (470 mg, 52%). δ_H (500 MHz, CDCl₃) 7.37-7.40 (m, 3H), 7.17-7.21 (m, 2H), 2.45 (s, 6H), 2.21 (q, *J* = 7.5, 4H), 1.20 (s, 6H), 0.90 (t, *J* = 7.6, 6H); δ_C (125 MHz, CDCl₃) 150.3, 138.9, 137.8, 136.0, 135.0, 131.4, 129.8, 128.5, 128.2, 17.7, 15.0, 14.5, 11.9; δ_B (160 MHz, CDCl₃) 0.65 (t, *J*_{B-F} = 32). NMR data matches that previously reported.⁶

1-Methyl-3,5,7-triethyl-2-ethylcarboxylato-8-*H*-4-bora-3a,4a-diaza-*s*-indacene (6BF₂)



Compound **6BF₂** was synthesized, from its corresponding free-base dipyrin. Bright orange solid (49 mg, 85 %). δ_{H} (500 MHz, CDCl₃) 7.19 (s, 1H), 6.28 (s, 1H), 4.31 (q, $J = 7.1$, 2H), 3.00 (q, $J = 7.6$, 2H), 2.91 (q, $J = 7.5$, 2H), 2.79 (s, 3H), 2.69 (q, $J = 7.5$, 2H), 1.37 (t, $J = 7.1$, 3H), 1.32 (t, $J = 7.6$, 3H), 1.28 (t, $J = 7.6$, 3H), 1.21 (t, $J = 7.5$, 3H); δ_{C} (125 MHz, CDCl₃) 167.4, 164.6, 157.7, 151.2, 148.6, 134.6, 130.4, 121.2, 117.38, 117.35, 60.0, 22.4, 19.5, 19.4, 16.8, 14.8, 14.5, 12.6 (1C missing); δ_{B} (160 MHz, CDCl₃) 0.86 (t, $J_{\text{B-F}} = 32$); LRMS-ESI (m/z): 385.2 [M + Na]⁺; HRMS-ESI (m/z): [M + Na]⁺ calcd for C₁₉H₂₅BF₂N₂NaO₂ 385.1869; found 385.1855.


3-Ethyl-6-methylpropanocarboxylato-2,5,7-trimethyl-2-8-*H*-4-bora-3a,4a-diaza-*s*-indacene (7BF₂)



Using **GPI**, compound **7BF₂** was synthesized from the corresponding free-base dipyrin.⁴ Bright orange solid (47 mg, 81 %). δ_{H} (500 MHz, CDCl₃) 7.42 (s, 1H), 7.08 (s, 1H), 3.69 (t, $J = 6.8$, 2H), 2.66 (t, $J = 6.8$, 2H), 2.61 (q, $J = 7.6$, 2H), 2.53 (s, 3H), 2.23 (s, 3H), 2.04 (s, 6H), 1.17 (t, $J = 7.6$, 3H); δ_{C} (125 MHz, CDCl₃) 178.9, 158.9, 143.5, 141.0, 140.2,


134.2, 132.02, 132.00, 125.3, 120.9, 62.2, 27.7, 18.1, 16.1, 13.2, 10.0, 9.9 (1C missing);
 δ_B (160 MHz, $CDCl_3$) 0.44 (t, $J_{B-F} = 32$).

8-Phenyl-4-bora-3a,4a-diaza-*s*-indacene (8BF₂**)**



Using **GP1**, compound **8BF₂** was synthesized from the corresponding free-base dipyririn.⁵
Red-orange solid (37 mg, 60%). δ_H (500 MHz, $CDCl_3$) 7.93-7.97 (m, 2H), 7.51-7.60 (m, 5H), 6.94 (d, $J = 3.6$, 2H), 6.55 (d, $J = 3.6$, 2H); δ_C (125 MHz, $CDCl_3$) 147.3, 144.0, 134.9, 133.7, 131.6, 130.7, 130.4, 128.4, 118.5; δ_B (160 MHz, $CDCl_3$) 0.28 (t, $J_{B-F} = 29$);
NMR data matches that previously reported.⁷


1,7-Bis(5-((*Z*)-(4-ethyl-3,5-dimethyl-2*H*-pyrrol-2-ylidene)methyl)-2,4-dimethyl-1*H*-pyrrol-3-yl)hexane dihydrobromide (9HBr**)**



Dibenzyl 4,4'-(hexane-1,7-diyl)bis(3,5-dimethyl-1*H*-pyrrole-2-carboxylate) (**11**, 1.5 g, 2.8 mmol) was dissolved in THF (30 mL) and a drop of triethylamine. 10% Pd/C (300


mg) was added to the solution, the flask was evacuated and refilled with H₂ (1 atm) and the reaction mixture then stirred overnight. The Pd/C was removed via filtration over Celite and another 300 mg of Pd/C was added to the solution. The flask was evacuated and refilled with H₂ (1 atm) once more and again stirred overnight. The Pd/C was removed via filtration over Celite and the solution was concentrated *in vacuo* to give **12** which was used in the next step without further purification. 2,4-Dimethyl-3-ethyl pyrrole-5-carboxaldehyde⁸ (**13**, 848 mg, 5.61 mmol) was added to a solution of the preceding bis(pyrrole) **12** in methanol:THF (1:6, 35 mL) and the solution was degassed by bubbling with nitrogen for 10 minutes. 48% aq. HBr (1 mL, 12 mmol) was then added dropwise, over 5 minutes, and the reaction mixture was stirred at room temperature under nitrogen for 1 hour. The reaction mixture was then concentrated *in vacuo* until little solvent remained. Diethyl ether was then added until a copious precipitate was evident. The precipitate was collected using filtration, dissolved in dichloromethane and the solution dried over Na₂SO₄. The solution was then concentrated *in vacuo* to give **9HBr** as a bright orange solid (1.67 g, 92% over 2 steps). δ_{H} (500 MHz, CDCl₃) 9.22 (s, 2H), 6.64 (s, 2H), 2.37 (q, $J = 7.5$, 4H), 2.32 (t, $J = 8$, 4H), 2.31 (s, 6H), 2.29 (s, 6H), 2.14 (s, 6H), 2.12 (s, 6H), 1.44-1.41 (m, 4H), 1.34-1.31 (m, 4H), 1.06 (t, $J = 7.5$, 6H); δ_{C} (125 MHz, CDCl₃) 151.5, 151.4, 136.8, 136.6, 133.8, 133.5, 130.1, 128.4, 115.4, 30.5, 29.5, 24.6, 17.9, 15.0, 14.6, 14.5, 9.8, 9.6; LRMS-ESI (m/z): 539.4 [M + Na]⁺; HRMS-ESI (m/z): [M + Na]⁺ calcd for C₃₆H₅₁N₄ 539.4108; found 539.4099.

**1,7-Bis(1,3,5,7-tetramethyl-2-ethyl-8-*H*-4-bora-3a,4a-diaza-*s*-indacene)hexane
(9BF₂)**



Compound **9BF₂** was synthesized, from its corresponding free-base dipyrin, and purified using **GP1** to give a bright red solid (32 mg, 54 %). δ_{H} (500 MHz, CDCl₃) 6.94 (s, 2H), 2.49 (s, 6H), 2.47 (s, 6H), 2.36 (q, $J = 7.3$, 8H), 2.16 (s, 6H), 2.14 (s, 6H), 1.40 (m, 8H), 1.06 (t, $J = 7.6$, 6H); δ_{C} (125 MHz, CDCl₃) 154.9, 154.8, 137.1, 136.8, 132.5, 131.8, 130.2, 128.9, 118.7, 30.3, 29.5, 24.2, 17.4, 14.7, 12.8, 12.7, 9.7, 9.5; δ_{B} (160 MHz, CDCl₃) 0.86 (t, $J_{\text{B-F}} = 32$); LRMS-ESI (m/z): 657.4 [$\text{M} + \text{Na}$]⁺; HRMS-ESI (m/z): [$\text{M} + \text{Na}$]⁺ calcd for C₃₆H₄₈B₂F₄N₄Na 657.3983; found 657.3884.


1,7-Bis(5-((*Z*)-(4-ethyl-3,5-dimethyl-2*H*-pyrrol-2-ylidene)methyl)-2,4-dimethyl-1*H*-pyrrol-3-yl)heptane dihydrobromide (10HBr)



Diethyl 4,4'-(heptane-1,7-diyl)bis(3,5-dimethyl-1*H*-pyrrole-2-carboxylate)⁹ (**14**, 410 mg, 0.952 mmol) was added to a suspension of potassium hydroxide (481 mg, 8.57 mmol) in ethylene glycol (10 mL) and the reaction mixture was heated at 200 °C, by means of a

sand bath, for one hour.⁸ After cooling to room temperature, the reaction mixture was separated between ethyl acetate (30 mL) and water (30 mL). The aqueous phase was extracted with ethyl acetate (3 x 20 mL) and combined organic extracts were washed with water (50 mL) and brine (50 mL), dried over anhydrous magnesium sulfate and concentrated *in vacuo* to give 1,7-bis(2,4-dimethyl-1H-pyrrol-3-yl)heptane (**15**), which was used in the next step without further purification. 2,4-Dimethyl-3-ethyl pyrrole-5-carboxaldehyde⁸ (**13**, 288 mg, 1.90 mmol) was added to a solution of the preceding bis(pyrrole) **15** in methanol:THF (1:1, 12 mL) and the solution was degassed by bubbling with nitrogen for 10 minutes.^{10,11} 48% aq. HBr (0.4 mL, 4.60 mmol) was then added drop-wise, over 5 minutes, and the reaction mixture was stirred at room temperature under nitrogen for 18 hours. The reaction mixture was then concentrated *in vacuo* until little solvent remained. Diethyl ether was then added until a copious precipitate was evident. The precipitate was collected using filtration, washed with 10% ethyl acetate in hexanes (10 mL) followed by diethyl ether (10 mL), and then dried using a vacuum oven to give the title compound (**10HBr**) as a brown solid (454 mg, 67% over 2 steps). δ_{H} (500 MHz, CDCl₃) 12.89 (brs, 4H), 7.03 (s, 2H), 2.66 (s, 6H), 2.64 (s, 6H), 2.44-2.37 (m, 8H), 2.26 (s, 6H), 2.25 (s, 6H), 1.45-1.39 (m, 4H), 1.31-1.25 (m, 6H), 1.07 (t, $J = 7.5$, 6H); δ_{C} (125 MHz, CDCl₃) 153.9, 153.8, 141.6, 141.4, 130.7, 129.0, 126.2, 126.1, 118.7, 30.0, 29.5, 29.4, 24.0, 17.3, 14.6, 13.1, 12.9, 10.3, 10.1; LRMS-ESI (m/z): 553.3 [M + H]⁺; HRMS-ESI (m/z): [M + H]⁺ calcd for C₃₇H₅₄N₄ 277.2169; found 277.2161.


1,7-Bis(1,3,5,7-tetramethyl-2-ethyl-8-*H*-4-bora-3a,4a-diaza-*s*-indacene)heptane (10BF₂)




Using **GP1**, compound **10BF₂** was synthesized from corresponding free-base dipyrin.

Red solid (26 mg, 45 %). δ_{H} (500 MHz, CDCl₃) 6.94 (s, 2H), 2.49 (s, 6H), 2.47 (s, 6H), 2.36 (td, $J = 7.3, 15.4$, 8H), 2.15 (s, 6H), 2.14 (s, 6H), 1.44-1.39 (m, 4H), 1.32-1.23 (m, 6H), 1.05 (t, $J = 7.6$, 6H); δ_{C} (125 MHz, CDCl₃) 155.0, 154.7, 137.1, 136.8, 132.5, 131.7, 130.3, 128.3, 118.7, 30.3, 29.6, 29.5, 24.2, 17.4, 14.7, 12.8, 12.7, 9.7, 9.5; δ_{B} (160 MHz, CDCl₃) 0.89 (t, $J_{\text{B-F}} = 33$); LRMS-ESI (m/z): 671.4 [M + Na]⁺; HRMS-ESI (m/z): [M + Na]⁺ calcd for C₃₇H₅₀B₂F₄N₄Na 671.4050; found 671.4047.

1,3,5,7-Tetramethyl-8-*H*-4-bora-3a,4a-diaza-*s*-indacene (4BF₂)




Compound **4BF₂** was obtained as a by-product in the formation of **2BF₂** using the traditional method involving excess BF₃•OEt₂ and NEt₃. δ_{H} (500 MHz, CDCl₃) 7.04 (s, 1H), 6.05 (s, 2H), 2.53 (s, 6H), 2.25 (s, 6H); δ_{C} (125 MHz, CDCl₃) 156.9, 141.3, 133.5, 120.2, 119.2, 14.8, 11.4; δ_{B} (160 MHz, CDCl₃) 0.76 (t, $J_{\text{B-F}} = 32$). NMR data matches that previously reported.⁶




Crystal data for compound **4BF₂**: C₁₃H₁₅BF₂N₂, MM = 248.08 g/mol, colourless needle crystal 0.29 x 0.22 x 0.12 mm; monoclinic, space group P2_{1/c} (#14), a = 11.700(6) Å, b = 14.423(2) Å, c = 11.934(3) Å, V = 1255.3(7) Å³, Z = 4, ρ = 1.313 g/cm³, μ(MoKα) = 1.54178 cm⁻¹, 2075 reflections (1162 unique, R_{int} = 0.067), R = 0.0554, R_w = 0.2073, GOF = 1.035.

1.4 NMR Spectra

1,3,5,7-Tetramethyl-2-octyl-8-*H*-4,4'-dichloro-bora-3a,4a-diaza-*s*-indacene (1BF₂) ¹³C NMR Spectrum in CDCl₃




1,3,5,7-Tetramethyl-2-ethyl-8-*H*-4,4'-dichloro-bora-3a,4a-diaza-*s*-indacene (2BF₂) ¹³C NMR Spectrum in CDCl₃




**3-Methyl-1,5,7-triethyl-2-ethylcarboxylato-8-*H*-4-bora-3a,4a-diaza-*s*-indacene
(6BF₂)**

¹³C NMR Spectrum in CDCl₃




1,3,6-Trimethyl-7-ethyl-2-8-*H*-4-bora-3a,4a-diaza-*s*-indacene (7BF₂)

¹³C NMR Spectrum in CDCl₃




**1,7-Bis(1,3,5,7-tetramethyl-2-ethyl-8-*H*-4-bora-3a,4a-diaza-*s*-indacene)hexane
(9BF₂)**

¹³C NMR Spectrum in CDCl₃




**1,7-Bis(5-((*Z*)-(4-ethyl-3,5-dimethyl-2*H*-pyrrol-2-ylidene)methyl)-2,4-dimethyl-1*H*-
pyrrol-3-yl)heptane dihydrobromide (10HBr)**

¹³C NMR Spectrum in CDCl₃



1,7-Bis(1,3,5,7-tetramethyl-2-ethyl-8-*H*-4-bora-3a,4a-diaza-*s*-indacene)heptane
(10BF₂)

¹³C NMR Spectrum in CDCl₃



1.4 References

- (1) Castro, A. J.; Gale, G. R.; Means, G. E.; Tertzakian, G. *J. Med. Chem.* **1967**, *10*, 29-32.
- (2) Tu, B.; Wang, C.; Ma, J. *Org. Prep. Proced. Int.* **1999**, *31*, 349-352.
- (3) Gabe, Y.; Urano, Y.; Kikuchi, K.; Kojima, H.; Nagano, T. *J. Am. Chem. Soc.* **2004**, *126*, 3357-3367.
- (4) Paine, J. B.; Hiom, J.; Dolphin, D. *J. Org. Chem.* **1988**, *53*, 2796-2802.
- (5) Rohand, T.; Dolusic, E.; Ngo, T. H.; Maes, W.; Dehaen, W. *ARKIVOC* **2007**, 307-324.
- (6) Crawford, S. M.; Thompson, A. *Org. Lett.* **2010**, *12*, 1424-1427.
- (7) Benniston, A. C.; Clift, S.; Harriman, A. *J. Mol. Sci.* **2011**, *985*, 346-354.
- (8) Jones, G.; Stanforth, S. P. *The Vilsmeier Reaction of Fully Conjugated Carbocycles and Heterocycles*, 2004.
- (9) Paine III, J. B.; Dolphin, D. *Can. J. Chem.* **1978**, *56*, 1710-1712.
- (10) Antina, E.; Guseva, G.; Dudina, N.; V'yugin, A.; Semeikin, A. *Russ. J. Gen. Chem.* **2009**, *79*, 2425-2434.
- (11) Beshara, C. S.; Pearce, B. M.; Thompson, A. *Can. J. Chem.* **2008**, *10*, 951-957.